Exchange: NASDAQ·Updated 07:30 PM EDT

DERM News

News
all
press releases
ELTP vs. DERM: Which Specialty Pharmaceutical Stock Is the Better Buy?
Elite Pharmaceuticals and Journey Medical follow different growth paths, but which looks more compelling now? Let's dive in.
Zacks
More News
Journey Medical (DERM) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
Here's What Key Metrics Tell Us About Journey Medical (DERM) Q2 Earnings
The headline numbers for Journey Medical (DERM) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks
Journey Medical Corporation (DERM) Reports Q2 Loss, Lags Revenue Estimates
Journey Medical (DERM) delivered earnings and revenue surprises of 0.00% and -1.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Heron Therapeutics (HRTX) Reports Q2 Loss, Lags Revenue Estimates
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -50.00% and -11.17%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Ardelyx (ARDX) Reports Q2 Loss, Lags Revenue Estimates
Ardelyx (ARDX) delivered earnings and revenue surprises of -40.00% and -2.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Merck KGaA (MKKGY) Soars 5.3%: Is Further Upside Left in the Stock?
Merck KGaA (MKKGY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks
Here's What Key Metrics Tell Us About Journey Medical (DERM) Q1 Earnings
The headline numbers for Journey Medical (DERM) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks
Journey Medical Corporation (DERM) Reports Q1 Loss, Beats Revenue Estimates
Journey Medical (DERM) delivered earnings and revenue surprises of -14.29% and +5.84%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Aurinia Pharmaceuticals (AUPH) Q1 Earnings and Revenues Top Estimates
Aurinia (AUPH) delivered earnings and revenue surprises of +38.89% and +0.39%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.